Skip to main content

Light-activated carriers for the controlled delivery of therapeutic peptides in posterior segment eye diseases

Project description

Light-activated nanocarriers for drug release in the eye

Macular degeneration and glaucoma are age-related eye diseases which are expected to increase in prevalence due to the rise in the ageing population. Since these diseases impair vision and hence quality of life, there is a need for efficient administration of therapeutics. The key objective of the EU-funded Light4Sight project is to develop a nanotechnology-based drug delivery system that contains therapeutic peptides within a light-sensitive hydrogel. The hydrogel can be injected in the vitreous, the clear gel that fills the space between the lens and the retina. Drug release will be activated by visible light in a controlled manner, avoiding toxicity while increasing the half-life of the therapeutic.

Coordinator

QUEEN MARY UNIVERSITY OF LONDON
Net EU contribution
€ 224 933,76
Address
327 Mile End Road
E1 4NS London
United Kingdom

See on map

Region
London Inner London — East Tower Hamlets
Activity type
Higher or Secondary Education Establishments
Other funding
€ 224 933,76